» Articles » PMID: 26921330

An Atlas of the Human Kinome Reveals the Mutational Landscape Underlying Dysregulated Phosphorylation Cascades in Cancer

Overview
Journal Cancer Res
Specialty Oncology
Date 2016 Feb 28
PMID 26921330
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Kinase inhibitors are used widely to treat various cancers, but adaptive reprogramming of kinase cascades and activation of feedback loop mechanisms often contribute to therapeutic resistance. Determining comprehensive, accurate maps of kinase circuits may therefore help elucidate mechanisms of response and resistance to kinase inhibitor therapies. In this study, we identified and validated phosphorylatable target sites across human cell and tissue types to generate PhosphoAtlas, a map of 1,733 functionally interconnected proteins comprising the human phospho-reactome. A systematic curation approach was used to distill protein phosphorylation data cross-referenced from 38 public resources. We demonstrated how a catalog of 2,617 stringently verified heptameric peptide regions at the catalytic interface of kinases and substrates could expose mutations that recurrently perturb specific phospho-hubs. In silico mapping of 2,896 nonsynonymous tumor variants identified from thousands of tumor tissues also revealed that normal and aberrant catalytic interactions co-occur frequently, showing how tumors systematically hijack, as well as spare, particular subnetworks. Overall, our work provides an important new resource for interrogating the human tumor kinome to strategically identify therapeutically actionable kinase networks that drive tumorigenesis. Cancer Res; 76(7); 1733-45. ©2016 AACR.

Citing Articles

A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF colorectal tumors.

Ruiz-Saenz A, Atreya C, Wang C, Pan B, Dreyer C, Brunen D Nat Cancer. 2023; 4(2):240-256.

PMID: 36759733 PMC: 9970872. DOI: 10.1038/s43018-022-00508-5.


Response and resistance to BRAF inhibition in gliomas: Roadblocks ahead?.

Capogiri M, De Micheli A, Lassaletta A, Munoz D, Coppe J, Mueller S Front Oncol. 2023; 12:1074726.

PMID: 36698391 PMC: 9868954. DOI: 10.3389/fonc.2022.1074726.


MAPPINGS, a tool for network analysis of large phospho-signalling datasets: application to host erythrocyte response to infection.

Adderley J, ODonoghue F, Doerig C, Davis S Curr Res Microb Sci. 2022; 3:100149.

PMID: 35909628 PMC: 9325900. DOI: 10.1016/j.crmicr.2022.100149.


A protein interaction landscape of breast cancer.

Kim M, Park J, Bouhaddou M, Kim K, Rojc A, Modak M Science. 2021; 374(6563):eabf3066.

PMID: 34591612 PMC: 9040556. DOI: 10.1126/science.abf3066.


Copy number aberrations drive kinase rewiring, leading to genetic vulnerabilities in cancer.

Memon D, Gill M, Papachristou E, Ochoa D, DSantos C, Miller M Cell Rep. 2021; 35(7):109155.

PMID: 34010657 PMC: 8149807. DOI: 10.1016/j.celrep.2021.109155.


References
1.
Forbes S, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H . COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2014; 43(Database issue):D805-11. PMC: 4383913. DOI: 10.1093/nar/gku1075. View

2.
Yuan Y, Van Allen E, Omberg L, Wagle N, Amin-Mansour A, Sokolov A . Assessing the clinical utility of cancer genomic and proteomic data across tumor types. Nat Biotechnol. 2014; 32(7):644-52. PMC: 4102885. DOI: 10.1038/nbt.2940. View

3.
Supek F, Minana B, Valcarcel J, Gabaldon T, Lehner B . Synonymous mutations frequently act as driver mutations in human cancers. Cell. 2014; 156(6):1324-1335. DOI: 10.1016/j.cell.2014.01.051. View

4.
Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H . Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007; 131(6):1190-203. DOI: 10.1016/j.cell.2007.11.025. View

5.
Brinkworth R, Breinl R, Kobe B . Structural basis and prediction of substrate specificity in protein serine/threonine kinases. Proc Natl Acad Sci U S A. 2002; 100(1):74-9. PMC: 140887. DOI: 10.1073/pnas.0134224100. View